PRRT: identikit of the perfect patient.
Neuroendocrine tumors
Peptide receptor radionuclide therapy
Predictor
Response
Therapeutic sequence
Journal
Reviews in endocrine & metabolic disorders
ISSN: 1573-2606
Titre abrégé: Rev Endocr Metab Disord
Pays: Germany
ID NLM: 100940588
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
27
9
2020
medline:
15
12
2021
entrez:
26
9
2020
Statut:
ppublish
Résumé
Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed. The aim of this review is to define the perfect identity of the eligible patient who can mostly benefit from this therapy. Possible predictive criteria which have been analysed were: primary tumor site, grading, tumor burden, FDG PET and
Identifiants
pubmed: 32978685
doi: 10.1007/s11154-020-09581-6
pii: 10.1007/s11154-020-09581-6
pmc: PMC8346456
doi:
Substances chimiques
Organometallic Compounds
0
Octreotide
RWM8CCW8GP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
563-579Informations de copyright
© 2020. The Author(s).
Références
Aalbersberg EA, Huizing DMV, Walraven I, de Wit-van der Veen BJ, Kulkarni HR, Singh A, et al. Parameters to predict progression-free and overall survival after peptide receptor radionuclide therapy: a multivariate analysis in 782 patients. J Nucl Med. 2019;60(9):1259–65. https://doi.org/10.2967/jnumed.118.224386 Epub 2019 Mar 8.
doi: 10.2967/jnumed.118.224386
pubmed: 30850483
Adnan A, Kudachi S, Ramesh S, Prabhash K, Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nucl Med Commun. 2019;40(9):947–57. https://doi.org/10.1097/MNM.0000000000001054 .
doi: 10.1097/MNM.0000000000001054
pubmed: 31343606
Alexandraki, et al. Current Concepts in the Diagnosis and Management of Neuroendocrine Neoplasms of Unknown Primary Origin. Minerva Endocrinol. 2019;44(4):378–86. https://doi.org/10.23736/S0391-1977.19.03012-8 .
doi: 10.23736/S0391-1977.19.03012-8
pubmed: 30991795
Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, et al. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine Tumours: a phase-II study. Theranostics. 2016;6(4):501–10. https://doi.org/10.7150/thno.13702 eCollection 2016.
doi: 10.7150/thno.13702
pubmed: 26941843
pmcid: 4775860
Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9(24):16932–50. https://doi.org/10.18632/oncotarget24524 eCollection 2018 Mar 30.
doi: 10.18632/oncotarget24524
pubmed: 29682195
pmcid: 5908296
Bertani E, Fazio N, Radice D, Zardini C, Grana C, Bodei L, et al. Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with Unresectable liver metastases. Ann Surg Oncol. 2016;23(Suppl 5):981–9.
doi: 10.1245/s10434-016-5550-3
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85. https://doi.org/10.1158/1078-0432.CCR-09-1759 .
doi: 10.1158/1078-0432.CCR-09-1759
Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with
doi: 10.1007/s00259-011-1902-1
pubmed: 21892623
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43(5):839–51. https://doi.org/10.1007/s00259-015-3250-z .
doi: 10.1007/s00259-015-3250-z
pubmed: 26596723
Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45(7):1155–69. https://doi.org/10.1007/s00259-018-3967-6 .
doi: 10.1007/s00259-018-3967-6
pubmed: 29484451
pmcid: 6716527
Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652–9. https://doi.org/10.1200/JCO.2009.22.8585 .
doi: 10.1200/JCO.2009.22.8585
pubmed: 20194865
pmcid: 4872330
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617–24. https://doi.org/10.1158/1078-0432.CCR-16-2743 .
doi: 10.1158/1078-0432.CCR-16-2743
pubmed: 28428192
Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28(10):1652–9. https://doi.org/10.1200/JCO.2009.22.8585 .
doi: 10.1200/JCO.2009.22.8585
pubmed: 20194865
pmcid: 4872330
Campana D, Capurso G, Partelli S, Nori F, Panzuto F, Tamburrino D, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. Eur J Nucl Med Mol Imaging. 2013;40(8):1197–205. https://doi.org/10.1007/s00259-013-2402-2 Epub 2013 Apr 26.
doi: 10.1007/s00259-013-2402-2
pubmed: 23619938
Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26(2):227–39. https://doi.org/10.1530/ERC-18-0424 .
doi: 10.1530/ERC-18-0424
pubmed: 30540557
clinicaltrials.gov. Available from: https://clinicaltrials.gov/ .
Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol. 2010;21(4):787–94. https://doi.org/10.1093/annonc/mdp372 .
doi: 10.1093/annonc/mdp372
pubmed: 19833821
Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014;43(4):518–25. https://doi.org/10.1097/MPA.0000000000000113 .
doi: 10.1097/MPA.0000000000000113
pubmed: 24632546
Demirci E, Kabasakal L, Toklu T, Ocak M, Şahin OE, Alan-Selcuk N, et al. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun. 2018;39(8):789–96. https://doi.org/10.1097/MNM.0000000000000874 .
doi: 10.1097/MNM.0000000000000874
pubmed: 29912750
Dumont RA, Seiler D, Marincek N, Brunner P, Radojewski P, Rochlitz C, et al. Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. Am J Nucl Med Mol Imaging. 2014;5(1):46–55 eCollection 2015.
pubmed: 25625026
pmcid: 4299770
Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011a;38(3):459–66. https://doi.org/10.1007/s00259-010-1610-2 .
doi: 10.1007/s00259-010-1610-2
pubmed: 20852858
Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med. 2011b;52(8):1197–203. https://doi.org/10.2967/jnumed.111.090373 .
doi: 10.2967/jnumed.111.090373
pubmed: 21764798
Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014a;41(5):925–33. https://doi.org/10.1007/s00259-013-2677-3 .
doi: 10.1007/s00259-013-2677-3
pubmed: 24504504
Ezziddin S, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014b;55(2):183–90. https://doi.org/10.2967/jnumed.113.125336 .
doi: 10.2967/jnumed.113.125336
pubmed: 24434296
Filice A, Fraternali A, Frasoldati A, Asti M, Grassi E, Massi L, et al. Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single Centre experience. J Oncol. 2012;2012:320198. https://doi.org/10.1155/2012/320198 .
doi: 10.1155/2012/320198
pubmed: 22934111
pmcid: 3425839
Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50(9):1427–34. https://doi.org/10.2967/jnumed.108.053421 .
doi: 10.2967/jnumed.108.053421
pubmed: 19690033
Gabriel M, Nilica B, Kaiser B, Virgolini IJ. Twelve-year follow-up after peptide receptor radionuclide therapy. J Nucl Med. 2019;60(4):524–9. https://doi.org/10.2967/jnumed.118.215376 .
doi: 10.2967/jnumed.118.215376
pubmed: 30115690
Grillo F, Albertelli M, Brisigotti MP, Borra T, Boschetti M, Fiocca R, et al. Grade increases in Gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor. Neuroendocrinology. 2016;103(5):452–9. https://doi.org/10.1159/000439434 .
doi: 10.1159/000439434
pubmed: 26337010
Grozinsky-Glasberg S, Barak D, Fraenkel M, Walter MA, Müeller-Brand J, Eckstein J, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer. 2011;117(7):1377–85. https://doi.org/10.1002/cncr.25646 .
doi: 10.1002/cncr.25646
pubmed: 21425137
Hamiditabar M, Ali M, Roys J, Wolin EM, TM OD, Ranganathan D, et al. Peptide receptor radionuclide therapy with 177Lu-Octreotate in patients with Somatostatin receptor expressing neuroendocrine tumors: six Years' assessment. Clin Nucl Med. 2017;42(6):436–43. https://doi.org/10.1097/RLU.0000000000001629 .
doi: 10.1097/RLU.0000000000001629
pubmed: 28263217
pmcid: 7733354
Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56. https://doi.org/10.2967/jnumed.110.075002 .
doi: 10.2967/jnumed.110.075002
pubmed: 20720050
Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al. Krause BJ5, Bengel FM4, Bartenstein P3, Biersack HJ7, Pöpperl G8, Baum RP. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: a multi-institutional registry study with prospective follow-up. Eur J Cancer. 2016;58:41–51. https://doi.org/10.1016/j.ejca.2016.01.009 .
doi: 10.1016/j.ejca.2016.01.009
pubmed: 26943056
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, et al. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2016;43(6):1040–6. https://doi.org/10.1007/s00259-015-3262-8 .
doi: 10.1007/s00259-015-3262-8
pubmed: 26611427
Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23. https://doi.org/10.1200/JCO.2010.33.7873 .
doi: 10.1200/JCO.2010.33.7873
pubmed: 21555692
Katona BW, Roccaro GA, Soulen MC, Yang YX, Bennett BJ, Riff BP, et al. Efficacy of peptide receptor radionuclide therapy in a United States-based cohort of metastatic neuroendocrine tumor patients: single-institution retrospective analysis. Pancreas. 2017;46(9):1121–6. https://doi.org/10.1097/MPA.0000000000000919 .
doi: 10.1097/MPA.0000000000000919
pubmed: 28902781
pmcid: 5659321
Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med. 2011;52(9):1361–8. https://doi.org/10.2967/jnumed.111.087932 .
doi: 10.2967/jnumed.111.087932
pubmed: 21795361
Knapp WH, Arnold R. Consensus protocol of the German Society of Nuclear Medicine and the section NET of the German Society of Endocrinology; workshop peptide receptor radionuclide therapy. Updated 2 December 2008. http://www.netregister.org/wDeutsch/ne_tumore/therapiemoeglichkeiten/peptid_radiorezeptor_therapie.php
Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17(3):313–8. https://doi.org/10.1007/s11307-014-0795-3 .
doi: 10.1007/s11307-014-0795-3
pubmed: 25319765
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–31.
doi: 10.1007/BF00181765
Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506.
doi: 10.1111/j.1749-6632.1994.tb17300.x
Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol. 1999;10(Suppl 2):S23–9.
doi: 10.1093/annonc/10.suppl_2.S23
Kunikowska J, Pawlak D, Bąk MI, Kos-Kudła B, Mikołajczak R, Królicki L. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017;31(5):347–56. https://doi.org/10.1007/s12149-017-1163-6 .
doi: 10.1007/s12149-017-1163-6
pubmed: 28316066
Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJM, Kooij PPM, De Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3] octreotate. Eur J Nucl Med Mol Imaging. 2003;30(3):417–22.
doi: 10.1007/s00259-002-1050-8
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005a;46(Suppl 1):62S–6S.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005b;23(12):2754–62.
doi: 10.1200/JCO.2005.08.066
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30. https://doi.org/10.1200/JCO.2007.15.2553 .
doi: 10.1200/JCO.2007.15.2553
pubmed: 18445841
Kwekkeboom DJ, Krenning EP. Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30(1):179–91. https://doi.org/10.1016/j.hoc.2015.09.009 .
doi: 10.1016/j.hoc.2015.09.009
pubmed: 26614376
Makis W, McCann K, McEwan AJ. The challenges of treating Paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor Lysis syndrome and the need for modification of treatment protocols. Nucl Med Mol Imaging. 2015;49(3):223–30. https://doi.org/10.1007/s13139-015-0332-6 .
doi: 10.1007/s13139-015-0332-6
pubmed: 26279696
pmcid: 4532685
Mariniello A, Bodei L, Tinelli C, Baio SM, Gilardi L, Colandrea M, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43(3):441–52. https://doi.org/10.1007/s00259-015-3190-7 .
doi: 10.1007/s00259-015-3190-7
pubmed: 26392198
Marincek N, Jörg AC, Brunner P, Schindler C, Koller MT, Rochlitz C, et al. Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. J Transl Med. 2013;11:17. https://doi.org/10.1186/1479-5876-11-17 .
doi: 10.1186/1479-5876-11-17
pubmed: 23320604
pmcid: 3561188
Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging. 2016;43(9):1585–92. https://doi.org/10.1007/s00259-016-3328-2 .
doi: 10.1007/s00259-016-3328-2
pubmed: 26922350
pmcid: 4932132
Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, et al. Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging. 2018;45(6):923–30. https://doi.org/10.1007/s00259-017-3925-8 .
doi: 10.1007/s00259-017-3925-8
pubmed: 29387927
Oh S, Prasad V, Lee DS, Baum RP. Effect of peptide receptor radionuclide therapy on Somatostatin receptor status and glucose metabolism in neuroendocrine tumors: Intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. Int J Mol Imaging 2011;2011:524130. doi: https://doi.org/10.1155/2011/524130 .
Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289–300. https://doi.org/10.1016/j.diii.2013.07.006 .
doi: 10.1016/j.diii.2013.07.006
pubmed: 24034971
Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014;41(10):1845–51. https://doi.org/10.1007/s00259-014-2735-5 .
doi: 10.1007/s00259-014-2735-5
pubmed: 24615468
Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008a;113(2):256–65. https://doi.org/10.1002/cncr.23549 .
doi: 10.1002/cncr.23549
pubmed: 18506737
Pape UF, Berndt U, Müller-Nordhorn J, Böhmig M, Roll S, Koch M, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008b;15(4):1083–97. https://doi.org/10.1677/ERC-08-0017 .
doi: 10.1677/ERC-08-0017
pubmed: 18603570
Parghane RV, Talole S, Prabhash K, Basu S. Clinical response profile of metastatic/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE. Clin Nucl Med. 2017;42(6):428–35. https://doi.org/10.1097/RLU.0000000000001639 .
doi: 10.1097/RLU.0000000000001639
pubmed: 28319500
Pencharz D, Walker M, Yalchin M, Quigley AM, Caplin M, Toumpanakis C. Navalkissoor S early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. Nucl Med Commun. 2017;38(7):593–600. https://doi.org/10.1097/MNM.0000000000000685 .
doi: 10.1097/MNM.0000000000000685
pubmed: 28471845
Pfeifer AK, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, et al. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology. 2011;93(3):189–96. https://doi.org/10.1159/000324096 .
doi: 10.1159/000324096
pubmed: 21335949
Sabet A, Khalaf F, Haslerud T, Al-Zreiqat A, Sabet A, Simon B, et al. Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am J Nucl Med Mol Imaging. 2013;3(5):437–45 eCollection 2013.
pubmed: 24116352
pmcid: 3784807
Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, et al. Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging. 2015;42(8):1238–46. https://doi.org/10.1007/s00259-015-3041-6 .
doi: 10.1007/s00259-015-3041-6
pubmed: 25808630
Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B. Bartenstein, P, Ezziddin, S. efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-Centre analysis. Am J Nucl Med Mol Imaging. 2017;7(2):74–83 eCollection 2017.
pubmed: 28533939
pmcid: 5435613
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44(3):490–9. https://doi.org/10.1007/s00259-016-3533-z .
doi: 10.1007/s00259-016-3533-z
pubmed: 27704193
Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23(6):824–33. https://doi.org/10.1038/modpathol.2010.58 .
doi: 10.1038/modpathol.2010.58
pubmed: 20305616
Scheidhauer K, Miederer M, Gaertner FC. PET-CT for neuroendocrine tumors and nuclear medicine therapy options. [Article in German]. Radiologe. 2009;49(3):217–23. https://doi.org/10.1007/s00117-008-1784-9 .
doi: 10.1007/s00117-008-1784-9
pubmed: 19296068
Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging. 2010;54(1):84–91.
pubmed: 20168290
Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, et al. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41(2):223–30.
doi: 10.1007/s00259-013-2578-5
Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S, et al. Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(6):881–8. https://doi.org/10.1007/s00259-013-2369-z .
doi: 10.1007/s00259-013-2369-z
pubmed: 23443937
Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, TM OD, et al. Peptide receptor radionuclide therapy outcomes in a north American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas. 2017;46(2):151–6. https://doi.org/10.1097/MPA.0000000000000734 .
doi: 10.1097/MPA.0000000000000734
pubmed: 27759712
pmcid: 5595066
Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol. 2019;141:108–15. https://doi.org/10.1016/j.radonc.2019.09.003 .
doi: 10.1016/j.radonc.2019.09.003
pubmed: 31542317
Sowa-Staszczak A, Pach D, Stefańska A, Tomaszuk M, Lenda-Tracz W, Mikołajczak R, et al. Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours? Nucl Med Rev Cent East Eur. 2011;14(2):73–8.
doi: 10.5603/NMR.2011.00019
Soydal Ç, Peker A, Özkan E, Küçük ÖN, Kir MK. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE. Turk J Med Sci. 2016;46(2):409–13. https://doi.org/10.3906/sag-1412-11 .
doi: 10.3906/sag-1412-11
pubmed: 27511504
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427 .
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Nucl Med Commun. 2016;37(10):1030–7. https://doi.org/10.1097/MNM.0000000000000547 .
doi: 10.1097/MNM.0000000000000547
pubmed: 27243215
Vaisman F, Rosado de Castro PH, Lopes FP, Kendler DB, Pessoa CH, Bulzico DA, et al. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer? Clin Nucl Med. 2015;40(2):123–7. https://doi.org/10.1097/RLU.0000000000000628 .
doi: 10.1097/RLU.0000000000000628
pubmed: 25546220
Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147–56.
doi: 10.1053/j.semnuclmed.2006.01.001
van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging. 2007;34(8):1219–27.
doi: 10.1007/s00259-006-0355-4
Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108(7):1440–8. https://doi.org/10.1038/bjc.2013.103 .
doi: 10.1038/bjc.2013.103
pubmed: 23492685
pmcid: 3629418
Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget. 2017;8(4, 7039):–7049. https://doi.org/10.18632/oncotarget.12402 .
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, et al. Pre-therapy Somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2019;21(3):582–90. https://doi.org/10.1007/s11307-018-1252-5 .
doi: 10.1007/s11307-018-1252-5
pubmed: 30014345
Yalchin M, Oliveira A, Theocharidou E, Pencharz D, Navalkissoor S, Quigley AM, et al. The impact of radiological response to peptide receptor radionuclide therapy on overall survival in patients with metastatic Midgut neuroendocrine tumors. Clin Nucl Med. 2017;42(3):e135–41. https://doi.org/10.1097/RLU.0000000000001457 .
doi: 10.1097/RLU.0000000000001457
pubmed: 27922860
Zovato S, Kumanova A, Demattè S, Sansovini M, Bodei L, Di Sarra D, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44(5):411–4. https://doi.org/10.1055/s-0032-1 .
doi: 10.1055/s-0032-1
pubmed: 22566197